Search This Blog

Monday, June 15, 2026

Neumora ends navacaprant after failed Phase 3 MDD trials

 

Neumora ends navacaprant after failed Phase 3 MDD trials and plans 35% workforce cut, extending cash runway into Q3 2027

  • Company expects planned 35% workforce reduction to generate about $10 million in annual savings.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)